Core Viewpoint - The company Kefu Medical announced an investment in Newlink Medical, focusing on advanced hearing rehabilitation solutions through brain-computer interface technology, particularly for congenital hearing loss [1] Group 1: Investment and Strategic Focus - Kefu Medical invested in Newlink Medical in May 2024, targeting offline hearing fitting centers [1] - The investment aims to create strategic synergy with the company's existing hearing business, especially in addressing congenital hearing loss [1] Group 2: Technological Development - Newlink Medical is developing bionic eyes and ears based on implanted brain-computer interface technology [1] - The company is exploring cutting-edge technologies to provide more effective solutions for hearing rehabilitation [1]

Group 1: Business Performance and Strategy - The company aims to enhance the operational quality of existing stores, with a reported revenue growth of over 20% year-on-year in the first half of 2025 [2] - The company plans to launch new products and strengthen online and offline channel collaboration to expand its hearing business [2] - The overseas business achieved nearly 100 million in revenue, with a year-on-year growth exceeding 200% [4] Group 2: Investments and Acquisitions - The company invested in NeuLink Medical in May 2024 to explore advanced hearing rehabilitation solutions through brain-machine interface technology [3] - In January 2025, the company completed a controlling acquisition of Shanghai Huazhou, enhancing its product line and overseas market channels [4] - The company also acquired a controlling stake in Ximan Na in June 2025, facilitating entry into the Hong Kong market [4] Group 3: Online Sales and Market Trends - The company has developed a comprehensive product matrix covering five major areas, maintaining strong sales performance on mainstream e-commerce platforms [6] - Interest e-commerce platforms have gained popularity, prompting the company to invest in innovative content to enhance brand visibility and product sales [6] Group 4: AI and Technology Development - The company is advancing AI applications across various medical devices, focusing on interconnectivity and data exchange [7] - The upcoming Kefu Health APP will integrate data from multiple devices to provide personalized health management solutions [7] Group 5: Core Product Strategy - The company focuses on core product categories that contribute significantly to revenue and have growth potential, including respiratory machines and hearing aids [8] - Continuous improvement in product quality and market share is a priority, with plans for iterative upgrades and cost reductions [8] Group 6: Respiratory Device Performance - The company's self-developed respiratory machines have received high consumer recognition, with sales rapidly increasing since late June 2025 [9]

近年来，智能机器人产业取得迅猛进展。高工机器人产业研究所日前发布的《2025年人形机器人产业发 展蓝皮书》（以下简称《蓝皮书》）预测，2025年全球人形机器人市场销量有望达到1.24万台，市场规 模63.39亿元；到2035年，全球人形机器人市场销量将超过500万台，市场规模将超过4000亿元。 然而，业内人士表示，尽管当前智能机器人在基础理论、性能效率等方面不断完善、快速迭代，但距离 能够批量满足各类场景需求的成熟产品，依然存在不小的差距。 "仿生视觉技术，能够加快机器人的产业化落地，全面走入社会生产、生活的各个场景。"日前，上海大 学仿生视觉与类脑智能研究所所长张晓林在"仿生视觉产业与投资研讨会"上表示。 仿生眼技术，即模仿生物视觉系统的人工智能视觉感知技术，是包含脑干、小脑、大脑功能的完整智能 仿生系统。与激光雷达、TOF和固定双目等现有技术相比，仿生眼拥有更加精确的识别、判断能力，同 时能够主动观察、注视目标物体及细节部位，是人工智能走向自主意识的关键要素。 张晓林表示，仿生技术的可动双眼设计，使摄像机的应用变得更加多样化，其动态特性具备防抖和跟踪 的能力，能够根据需要切换视角，观察任何想要观察的地方 ...